

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Glenmark Pharmaceuticals Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	HSBC GLOBAL ASSET MANAGEMENT (HONG KONG) LIMITED		
Whether the acquirer belongs to Promoter/Promoter group	NA		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange BSE		
Details of the acquisition as follows	Number/ Share	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC(*)
<u>Before the acquisition under consideration, holding of acquirer along with PACs of:</u> a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category) e) Total (a+b+c+d)	a) 14,029,081 = Total	4.97%	
<u>Details of acquisition</u> a) Shares carrying voting rights acquired/sold b) VRs acquired /sold otherwise than by shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold d) Shares encumbered / invoked/released by the acquirer e) Total (a+b+c+/-d)	a) 204,615 = Total	0.07%	
<u>After the acquisition, holding of acquirer along with PACs of:</u> a) Shares carrying voting rights b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d)	a) 14,233,696 = Total	5.04%	
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market Purchase		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	24 September 2020		
Equity share capital / total voting capital of the TC before the said acquisition	282,168,156		

Equity share capital/ total voting capital of the TC after the said acquisition	282,168,156
Total diluted share/voting capital of the TC after the said acquisition	282,168,156

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Part-B

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquire and/ or PACs
HSBC GLOBAL ASSET MANAGEMENT (HONG KONG) LIMITED	NA	



Katie Lau

Associate Director, Regulatory Compliance

HSBC Global Asset Management (Hong Kong) Limited

Place : Hong Kong

Date : 29 September 2020